| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
54,750,000 |
| Market
Cap: |
763.22(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.78 - $18.08 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile uniQure is engaged in the field of gene therapy, focusing to develop single treatments for patients suffering from genetic and other diseases. Co. is developing etranacogene dezaparvovec, a gene therapy for patients with hemophilia B that is designed to restore Factor IX (FIX) activity, a protein for blood clotting. Etranacogene dezaparvovec includes an adeno-associated virus (AAV) 5 vector incorporating the FIX-Padua variant. Co. is also developing AMT-180 for hemophilia A, AMT-190 for fabry disease, and AMT-130 for huntington's disease. Co.'s AMT-150 is a one-time, intrathecally-administered, AAV gene therapy incorporating Co.'s miQURE™ silencing technology.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
20,678 |
118,584 |
223,798 |
327,872 |
| Total Sell Value |
$302,017 |
$1,336,230 |
$2,878,869 |
$3,583,880 |
| Total People Sold |
8 |
11 |
11 |
14 |
| Total Sell Transactions |
8 |
16 |
19 |
36 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kaye Jack |
Director |
– • – |
2025-06-20 |
4 |
S |
$14.45 |
$30,518 |
D/D |
(2,112) |
20,439 |
|
2% |
|
| Post Leonard E |
Director |
– • – |
2025-06-20 |
4 |
S |
$14.45 |
$30,518 |
D/D |
(2,112) |
29,937 |
|
2% |
|
| Gut Robert |
Director |
– • – |
2025-06-20 |
4 |
S |
$14.45 |
$48,205 |
D/D |
(3,336) |
56,879 |
|
2% |
|
| Meek David D. |
Director |
– • – |
2025-06-20 |
4 |
S |
$14.45 |
$30,518 |
D/D |
(2,112) |
34,190 |
|
2% |
|
| Springhorn Jeremy P. |
Director |
– • – |
2025-06-20 |
4 |
S |
$14.45 |
$30,518 |
D/D |
(2,112) |
37,694 |
|
2% |
|
| Jacques Rachelle Suzanne |
Director |
– • – |
2025-06-20 |
4 |
S |
$14.45 |
$30,518 |
D/D |
(2,112) |
28,346 |
|
2% |
|
| Balachandran Madhavan |
Director |
– • – |
2025-06-20 |
4 |
S |
$14.45 |
$30,518 |
D/D |
(2,112) |
37,697 |
|
2% |
|
| Potts Jeannette |
Chief Legal Officer |
• – – |
2025-06-16 |
4 |
S |
$15.14 |
$70,704 |
D/D |
(4,670) |
115,073 |
|
8% |
|
| Jacques Rachelle Suzanne |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
7,970 |
30,458 |
|
- |
|
| Post Leonard E |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
7,970 |
32,049 |
|
- |
|
| Springhorn Jeremy P. |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
7,970 |
39,806 |
|
- |
|
| Balachandran Madhavan |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
7,970 |
39,809 |
|
- |
|
| Meek David D. |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
7,970 |
36,302 |
|
- |
|
| Gut Robert |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
7,970 |
60,215 |
|
- |
|
| Kaye Jack |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
7,970 |
22,551 |
|
- |
|
| Klemt Christian |
Chief Financial Officer |
• – – |
2025-03-04 |
4 |
S |
$10.29 |
$107,407 |
D/D |
(10,438) |
217,730 |
|
-22% |
|
| Kapusta Matthew C |
CEO, Managing Director |
• • – |
2025-03-04 |
4 |
S |
$10.29 |
$291,629 |
D/D |
(28,341) |
651,454 |
|
-22% |
|
| Abi-Saab Walid |
Chief Medical Officer |
• – – |
2025-03-04 |
4 |
S |
$10.29 |
$13,892 |
D/D |
(1,350) |
151,903 |
|
-22% |
|
| Potts Jeannette |
Chief Legal Officer |
• – – |
2025-03-04 |
4 |
S |
$10.29 |
$72,812 |
D/D |
(7,076) |
119,743 |
|
-22% |
|
| Klemt Christian |
Chief Financial Officer |
• – – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
73,000 |
228,168 |
|
- |
|
| Kapusta Matthew C |
CEO, Managing Director |
• • – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
99,000 |
679,795 |
|
- |
|
| Abi-Saab Walid |
Chief Medical Officer |
• – – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
38,000 |
153,253 |
|
- |
|
| Potts Jeannette |
Chief Legal Officer |
• – – |
2025-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
126,819 |
|
- |
|
| Klemt Christian |
Chief Financial Officer |
• – – |
2025-02-27 |
4 |
S |
$11.32 |
$33,009 |
D/D |
(2,916) |
155,168 |
|
-15% |
|
| Kapusta Matthew C |
CEO, Managing Director |
• • – |
2025-02-27 |
4 |
S |
$11.32 |
$76,036 |
D/D |
(6,717) |
580,795 |
|
-15% |
|
390 Records found
|
|
Page 1 of 16 |
|
|
0.08 (0.58%) 
